Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Azacitidine in t-MDS
NCT05379166Phase 2Active, not recruiting
- Start
- Jun 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in therapy-related myelodysplastic syndrome (t-MDS). Started Jun 2022; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
therapy-related myelodysplastic syndrome (t-MDS)
Beyond the preview
Go deeper on NCT05379166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05379166.